Navigation Links
Plethora and Paul Capital Healthcare sign a $25 million revenue interest financing agreement with an option for an additional $3 million equity investment
Date:4/1/2008

eiler Tel: 1 206 713 0124

Email: sseiler@lazarpartners.com

About Paul Capital Partners and Paul Capital Healthcare

Through its multiple funds, Paul Capital Healthcare is one of the largest dedicated healthcare investors globally, with $1.8 billion in equity capital commitments and debt facilities under management. Combined, the Paul Capital Healthcare funds have invested more than $900 million in the pharmaceutical, biotechnology, and medical device sectors. These investments are focused on commercial stage companies and products, and consist of investments in the form of royalties, revenue interests, debt and equity. Additional information on Paul Capital Healthcare can be found at http://www.paulcapitalhealthcare.com. Paul Capital Partners manages nearly $5 billion in equity capital commitments for its three investment platforms, which include Paul Capital Healthcare, Private Equity Secondaries and Top Tier Fund-of-Funds. The firm has offices in New York, San Francisco, Paris, London and Toronto.

About Plethora:

Plethora is focused on the development and marketing of products for the treatment of urological disorders. The Company has products in clinical development for the treatment of overactive bladder, stress urinary incontinence, interstitial cystitis, gynaecological pain, erectile dysfunction and premature ejaculation. In January 2006, Plethora acquired Minneapolis- based Timm Medical Technologies, Inc., which markets products for the treatment of erectile dysfunction (ED) to urology clinics through a US-based specialty sales team. The Company is headquartered in the UK and is listed on the London Stock Exchange (AIM: PLE) Further information is available at http://www.plethorasolutions.co.uk. <
'/>"/>

SOURCE Paul Capital Healthcare
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Vermillion Meets Minimum Bid Price and Receives NASDAQ Staff Determination Letter for Minimum Market Capitalization
2. Pharmasset Receives $10 Million of Working Capital
3. Alexza Completes $10 Million Equity Financing with Bio*One Capital to Initiate Commercial Manufacturing in Singapore
4. Insmed Announces Listing Transfer from Nasdaq Global Market to Nasdaq Capital Market
5. Bio-Clean International, Inc. to Present at Bluechip Capital Investment Forum
6. National Stem Cell Holding, Inc. Has Engaged BMA Securities to Assist and Advise the Company With Its Current Capital Raise of $3,500,000
7. AEterna Zentaris to Present at the Upcoming Roth Capital Partners 20th Annual OC Growth Stock Conference in Dana Point, California
8. AspenBio Pharma to Present at the Roth Capital Partners 20th Annual Growth Stock Conference
9. CryoLife to Present at Roth Capital Partners 20th Annual Orange County (OC) Growth Stock Conference
10. WaferGen to Present at the Roth Capital Partners 20th Annual OC Growth Stock Conference
11. Ardea Biosciences to Present at Roth Capital Partners 20th Annual OC Growth Stock Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/22/2014)... Mass. , Sept. 22, 2014 ... GEVA ), a biopharmaceutical company developing therapeutic ... of Robert Bazemore as Chief Operating ... , President and Chief Executive Officer, Robert will ... company,s lead program, sebelipase alfa for LAL Deficiency, ...
(Date:9/20/2014)... (PRWEB) September 20, 2014 Entries are ... Prism Awards for Photonics Innovation . The international ... multi-billion dollar optics and photonics industry, and is sponsored ... photonics , and Photonics Media . , The ... versatility of photonics, said SPIE CEO Eugene Arthurs. , ...
(Date:9/19/2014)... NEW YORK, September 18, 2014 Scientists at NYU ... boost dramatically the efficiency of the process for turning ... three well-known compounds, including vitamin C. Using the new ... stem cells obtained from adult skin cells by more ... their technique is efficient and reliable, and thus should ...
(Date:9/19/2014)... Sept. 19, 2014  Nektar Therapeutics (NASDAQ: ... studies characterizing the analgesic profiles of a series ... receptor agonist molecules. The preclinical research candidates were ... platform. The analgesic properties of kappa ... literature. 1,2 Kappa opioid receptors are expressed ...
Breaking Biology Technology:Synageva BioPharma Appoints Robert Bazemore As Chief Operating Officer 2Synageva BioPharma Appoints Robert Bazemore As Chief Operating Officer 3Synageva BioPharma Appoints Robert Bazemore As Chief Operating Officer 4Entry deadline is 10 October for international photonics Prism Awards 2Entry deadline is 10 October for international photonics Prism Awards 3Entry deadline is 10 October for international photonics Prism Awards 4NYU Langone scientists report reliable and highly efficient method for making stem cells 2NYU Langone scientists report reliable and highly efficient method for making stem cells 3Nektar Presents Positive Preclinical Data on Oral, Peripherally-Acting Kappa Agonist Molecules at 2014 American Academy of Pain Management Meeting 2Nektar Presents Positive Preclinical Data on Oral, Peripherally-Acting Kappa Agonist Molecules at 2014 American Academy of Pain Management Meeting 3Nektar Presents Positive Preclinical Data on Oral, Peripherally-Acting Kappa Agonist Molecules at 2014 American Academy of Pain Management Meeting 4Nektar Presents Positive Preclinical Data on Oral, Peripherally-Acting Kappa Agonist Molecules at 2014 American Academy of Pain Management Meeting 5
... detect broken bones, tumors and dental cavities, analyze atoms in ... knew they could cause crystals to form? A team ... the formation of a new type of crystal: charged cylindrical ... which is unknown in crystals. Similar phenomena may occur naturally ...
... , , , , ... 25 /PRNewswire-Asia/ -- China,Yongxin Pharmaceuticals, Inc. (OTC Bulletin Board: ... distributor and,retailer of Chinese traditional medicines, pharmaceutical products, natural,health products, ... The Company today announced that it plans to open twenty ...
... , ... ,Amsterdam Molecular Therapeutics (Euronext: AMT), a leader in ... important milestone in the official,marketing authorisation process for ... lipase deficiency (LPLD). The submission,of the Glybera(R) Marketing ...
Cached Biology Technology:Surprising discovery: X-rays drive formation of new crystals 2China Yongxin Pharmaceuticals Plans to Open Eighteen New Stores in 2010 to Further Expand Customer Base and Increase Market Share 2China Yongxin Pharmaceuticals Plans to Open Eighteen New Stores in 2010 to Further Expand Customer Base and Increase Market Share 3China Yongxin Pharmaceuticals Plans to Open Eighteen New Stores in 2010 to Further Expand Customer Base and Increase Market Share 4EMA Starts Formal Review of Glybera(R) Dossier 2EMA Starts Formal Review of Glybera(R) Dossier 3
(Date:9/18/2014)... N.Y. A sleep-promoting circuit located deep in the ... sleep. Discovered by researchers at Harvard School of Medicine ... Biomedical Sciences, this is only the second "sleep node" ... be both necessary and sufficient to produce deep sleep. ... , the study demonstrates that fully half of all ...
(Date:9/18/2014)... robotic system that can operate inside the bore of ... of a biomedical research partnership program at Brigham and ... if the robot, in conjunction with real-time MRI images, ... costly, and less discomforting for the patient. The novel ... therapies with greater precision. , Developed by a team ...
(Date:9/18/2014)... many times it,s demonstrated, it,s still hard to ... But by using a signaling system called "quorum ... to suit their population. In short, some bacteria ... act accordingly. , Once the population of quorum-sensing ... innocuous to pathogenic, or from unhelpful to helpful. ...
Breaking Biology News(10 mins):No sedative necessary: Scientists discover new 'sleep node' in the brain 2Trial begins for MRI-compatible robot designed to improve accuracy of prostate biopsies 2Trial begins for MRI-compatible robot designed to improve accuracy of prostate biopsies 3Trial begins for MRI-compatible robot designed to improve accuracy of prostate biopsies 4Trial begins for MRI-compatible robot designed to improve accuracy of prostate biopsies 5Researchers study vital 'on/off switches' that control when bacteria turn deadly 2Researchers study vital 'on/off switches' that control when bacteria turn deadly 3
... of the world,s biggest killers for as long as records ... the rise, there is a renewed push to find different ... have stepped up to the plate to answer the call. ... department of chemical and biomolecular engineering, recently were awarded a ...
... Now computers are at it again, but this ... itself. An interdisciplinary team of scientists at Vanderbilt ... taken a major step toward this goal by demonstrating ... a biological system and derive the basic mathematical equations ...
... has been associated with cognitive decline, characterized by a ... thought-processing speed. But in a study of 300 post-menopausal ... in Argentina, obese participants in the study performed better ... leading researchers to speculate about the role of sex ...
Cached Biology News:UH engineers finding new ways to fight malaria with DOD grant 2Robot biologist solves complex problem from scratch 2Robot biologist solves complex problem from scratch 3Association between menopause, obesity and cognitive impairment 2
Mitochondria/Cytosol Fractionation Kit Research Focus: other Storage Temperature: 4C Shipping Temperature: 4C...
... increasing age, the autofluorescent pigment lipofuscin ... cell types, including neurons. The presence ... use of fluorescence microscopy in the ... broad excitation and emission spectra, which ...
... the family of calcium binding proteins such as ... of an alpha and beta chain whereas S100B ... protein is also expressed in the antigen presenting ... and interdigitating reticulum cells in the paracortex of ...
LEAF™ Purified anti-human/mouse/rat ICOS...
Biology Products: